130 related articles for article (PubMed ID: 15867944)
41. Antiaggregatory effects of thromboxane receptor antagonists in vivo.
Darius H; Lefer AM
Thromb Res; 1985 Dec; 40(5):663-75. PubMed ID: 2935972
[TBL] [Abstract][Full Text] [Related]
42. Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig.
Tchana-Sato V; Dogné JM; Lambermont B; Ghuysen A; Magis D; Morimont P; Hanson J; D'Orio V; Limet R; Kolh P
Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):82-95. PubMed ID: 16303607
[TBL] [Abstract][Full Text] [Related]
43. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
[TBL] [Abstract][Full Text] [Related]
44. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review.
Fiddler GI; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820
[TBL] [Abstract][Full Text] [Related]
45. Biosynthesis and pharmacological modulation of thromboxane in humans.
Patrono C
Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814
[TBL] [Abstract][Full Text] [Related]
46. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
Tubaro E; Belogi L; Mezzadri CM
Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
[TBL] [Abstract][Full Text] [Related]
47. Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule.
Ohshima E; Sato H; Obase H; Miki I; Ishii A; Kawakage M; Shirakura S; Karasawa A; Kubo K
J Med Chem; 1993 May; 36(11):1613-8. PubMed ID: 8496929
[TBL] [Abstract][Full Text] [Related]
48. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
49. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
50. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
51. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
[TBL] [Abstract][Full Text] [Related]
53. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
[TBL] [Abstract][Full Text] [Related]
54. Thromboxane synthetase inhibition and thromboxane receptor blockade preserve pulmonary and circulatory function in a porcine burn sepsis model.
Iglesias G; Zeigler ST; Lentz CW; Traber DL; Herndon DN
J Am Coll Surg; 1994 Aug; 179(2):187-92. PubMed ID: 8044389
[TBL] [Abstract][Full Text] [Related]
55. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
Heylen L; De Clerck F; Somers Y; Leysen JE
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
[TBL] [Abstract][Full Text] [Related]
56. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.
Gresele P; Deckmyn H; Nenci GG; Vermylen J
Trends Pharmacol Sci; 1991 Apr; 12(4):158-63. PubMed ID: 1829559
[TBL] [Abstract][Full Text] [Related]
57. Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.
Michaux C; Rolin S; Dogné JM; Durant F; Masereel B; Delarge J; Wouters J
Bioorg Med Chem Lett; 2001 Apr; 11(8):1019-22. PubMed ID: 11327579
[TBL] [Abstract][Full Text] [Related]
58. Effects of BM-573, a novel thromboxane A2 inhibitor, on pulmonary hemodynamics in endotoxic shock.
Lambermont B; Ghuysen A; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Benoit P; Gérard P; Masereel B; D'Orio V
Arch Physiol Biochem; 2003 Jul; 111(3):224-31. PubMed ID: 14972744
[TBL] [Abstract][Full Text] [Related]
59. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors.
Cimetière B; Dubuffet T; Landras C; Descombes JJ; Simonet S; Verbeuren TJ; Lavielle G
Bioorg Med Chem Lett; 1998 Jun; 8(11):1381-6. PubMed ID: 9871770
[TBL] [Abstract][Full Text] [Related]
60. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
